
Boehringer Ingelheim announces results from phase 2 trial for liver disease treatment
Betsy Goodfellow | February 26, 2024 | News story | Research and Development | Boehringer Ingelheim, Hepatology, clinical trial, liver disease, survodutide
Boehringer Ingelheim has announced results from the phase 2 trial of survodutide for the treatment of liver disease due to metabolic dysfunction-associated steatohepatitis (MASH).
The trial demonstrated that 83% of adults treated with the drug achieved a statistically significant improvement of MASH compared to placebo (18.2%). The trial met its primary endpoint of reaching a biopsy-proven improvement in MASH after 48 weeks, without the worsening of fibrosis stages F1, F2 and F3 (mild to moderate or advanced scarring).
The drug also met all of its secondary endpoints, such as a statistically significant improvement in liver fibrosis.
It is expected that full data will be presented in the next few months.
Dr Arun Sanyal MD professor of medicine, physiology and molecular pathology at Virginia Commonwealth University School of Medicine, US, and principal investigator on the trial, commented: “I am thrilled to see these statistically significant results from the phase 2 trial of survodutide in MASH and fibrosis. These data position survodutide as a potential leading treatment for a population with great unmet medical needs, and will bring hope to people living with MASH and with fibrosis. I am looking forward to sharing further detail on key secondary endpoints, including the percentage of adults who saw an improvement in fibrosis, at a congress in the first half of this year.”
Betsy Goodfellow
Related Content

Tridem begins phase Ib trial of Parkinson’s disease vaccine
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …

How will biomarker-led diagnostics reshape respiratory medicine?
By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed …

Cell therapy partnership aims to bring liver disease treatment closer to US patients
Resolution Therapeutics has partnered with the Blood Centers of America (BCA) to support community-based delivery …






